Research Article
Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats
Table 6
Decreasing plasma protein levels (mean ± SD) in combined male and female groups with increasing doses of drug.
| | Day | Dose(s) | Buprenorphine dose group | | Control | 1.3 mg/kg | 3.9 mg/kg | 6.5 mg/kg |
| | Total protein g/dL | | 2 | 1 | 5.9 ± 0.3 | 5.9 ± 0.2 | 5.7 ± 0.3 | 5.4 ± 0.4 | | 4 | 1 | 5.7 ± 0.3 | 5.6 ± 0.1 | 5.6 ± 0.4 | 5.5 ± 0.2 | | 6 | 2 | 5.8 ± 0.4 | 5.6 ± 0.2 | 5.5 ± 0.3 | 5.4 ± 0.2 | | 12 | 3 | 5.8 ± 0.4 | 5.6 ± 0.5 | 5.5 ± 0.4 | 5.6 ± 0.1 |
| | Albumin g/dL | | 2 | 1 | 3.2 ± 0.2 | 3.1 ± 0.2 | 2.9 ± 0.2 | 2.8 ± 0.2 | | 4 | 1 | 3.0 ± 0.2 | 3.0 ± 0.1 | 3.0 ± 0.2 | 2.9 ± 0.1 | | 6 | 2 | 3.2 ± 0.3 | 3.1 ± 0.1 | 2.8 ± 0.2 | 2.7 ± 0.1 | | 12 | 3 | 3.2 ± 0.2 | 3.2 ± 0.3 | 2.95 ± 0.2 | 2.8 ± 0.1 |
|
|
